Cargando…
Efficacy of Levofloxacin and Rifaximin based Quadruple Therapy in Helicobacter pylori Associated Gastroduodenal Disease: A Double-Blind, Randomized Controlled Trial
The aim of this study was to evaluate the efficacy of levofloxacin and rifaximin based quadruple regimen as first-line treatment for Helicobacter pylori infection. A prospectively randomized, double-blinded, parallel group, comparative study was performed. Three hundred consecutive H. pylori positiv...
Autores principales: | Choi, Kang Hyun, Chung, Woo Chul, Lee, Kang-Moon, Paik, Chang Nyol, Kim, Eun Jung, Kang, Bong Koo, Oak, Ju Hyun, Jung, Sung Hoon |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102873/ https://www.ncbi.nlm.nih.gov/pubmed/21655065 http://dx.doi.org/10.3346/jkms.2011.26.6.785 |
Ejemplares similares
-
Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori
por: Yun, Sang-Pil, et al.
Publicado: (2012) -
Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment of Helicobacter pylori Infection in Korea
por: Moon, Ji Yoon, et al.
Publicado: (2013) -
The Comparison of Levofloxacin- and Clarithromycin-Based Bismuth Quadruple Therapy Regimens in Helicobacter pylori Eradication
por: Arj, Abbas, et al.
Publicado: (2020) -
The Efficacy, Safety, and Tolerability of Levofloxacin Quadruple Therapy for Helicobacter pylori Eradication: A Randomized, Double-Blind Clinical Trial
por: Mansour-Ghanaei, Fariborz, et al.
Publicado: (2022) -
Seven Days of Bismuth-Based Quadruple Therapy Is as Effective for the First-Line Treatment of Clarithromycin-Resistant Confirmed Helicobacter pylori Infection as 14 Days of Bismuth-Based Quadruple Therapy
por: Moon, Sang-Gon, et al.
Publicado: (2022)